Printer Friendly

Mortality in a Cohort of HIV-infected Children: A 12-Month Outcome of Antiretroviral Therapy in Makurdi, Nigeria.

1. Introduction

In 2014, about 58,000 new HIV infections occurred among children in Nigeria, making the country to be the largest harbourer of new childhood HIV infections among the 22 Global Plan Priority Countries committed to curbing HIV epidemics [1, 2]. Unfortunately, only 12% of Nigerian children (aged 0-14 years) living with HIV received antiretroviral therapy (ART) in 2014 [1]. Without ART, half of the HIV-infected children tend to die before their 2nd birthday [3-5]. The proportion of HIV deaths remains higher in resource-limited countries (RLCs) [6-13] compared to resource-rich countries (RRC) [14-16] because of pervasive weak health systems, poor socioeconomic conditions, and a relative suboptimal care for HIV-infected children. The unacceptably high HIV-related mortality in RLCs is also linked to the use of suboptimal antiretroviral regimens, nonadherence to ART, ART discontinuation as a result of drug toxicities, and the propensity for resistant viral strains [17].

Some of the challenges facing paediatric ART expansion in Nigeria and in other RLC include suboptimal provider-initiated counseling and testing in health facilities; problems with early infant diagnosis; inadequate ART centres; shortage of skilled health personnel; lack of appropriate paediatric antiretroviral formulations; and noninvolvement of private health facilities and noncommittal of the government at the local level, to mention just a few [18, 19].

ART is expected to restore immune functions, maintain maximal suppression of viral replications, and reduce HIV-related morbidity and mortality, and improve quality of life, and thus, expected to prolong the survival of HIV-infected individuals [20].

However, in children, a high HIV viremia due to the deleterious impacts of the HIV on the immature thymus and the varying response to ART across paediatric age groups makes the response to ART distinct in children compared to adult populations [21-23].

While few studies [24-26] have reported the outcomes of HIV-infected Nigerian children to ART, only two [24, 26] did an in-depth analysis of baseline factors that may predict mortality. Thus, there is the need for more studies in Nigeria to explore the factors that may predict mortality upon the initiation of children on ART, as this knowledge may allow for close management and/or modification of these predictors of mortality.

This study, therefore, aims at describing the determinants of mortality in a cohort of children that were initiated and followed up on ART for 12 months at the Federal Medical Centre (FMC), Makurdi, Nigeria, between October 2010 and December 2013.

2. Methods

2.1. Study Area and Setting. This report is from the paediatric HIV care and treatment (PHCT) programme of the FMC, Makurdi, which is supported by the AIDS Prevention Initiative in Nigeria (APIN)/Harvard PEPFAR (The USA President's Emergency Plan for AIDS Relief). The PHCT had commenced a comprehensive care in May 2006. The details of the study setting have been reported elsewhere [27] as the authors had earlier reported the burden of tuberculosis in the same cohort of HIV-infected children.

Two paediatricians and 8 paediatric residents provided the HIV care and treatment in the clinic that is run twice weekly, on Wednesdays and Fridays. Between May 2006 and December 2013, about 1,278 children were already in care, of which 834 had been initiated on ART [27]. ART was commenced on children only if they were confirmed to be HIV-1 infected. Confirmation of HIV infection among infants less than 18 months old required two positive results from HIV DNA/PCR. A double rapid HIV antibody test using Determine HIV 1/2 first and Chembio HIV 1/2 STATPAK in a serial algorithm (confirmed with Western blot) denotes HIV infection for children [greater than or equal to] 18 months. Children were seen at clinical follow-ups which were scheduled as follows: monthly for the first three months, every 3-month in the first year, and thereafter, every 6-month. During each scheduled follow-up and at any time when children visit the clinic, the following were also noted including the growth parameters, the viral load, the CD4 counts, and comorbidity/opportunistic infection. The flow cytometry method was used for [CD4.sup.+] T lymphocyte (CD4) count measurement, and HIV-1 RNA viral load was also measured.

2.2. Ethical Consideration. The Research and Ethics Committee (REC) of the FMC, Makurdi, provided permission for the use of the patients' data for this study. Also, at recruitment of the HIV-infected children in our ART programme, parents or caregivers of these children provided written informed consent for the use of their data for research as would be approved by the REC of FMC, Makurdi.

2.3. Study Design and Population. It was a retrospective analysis of available data (sociodemographics, clinical/ laboratory, diagnosed comorbidities/opportunistic infections, and mortality) collected among HIV-infected children aged 15 years of age or less, between October 2010 and December 2013. At this period, enrolment into the ART programme is optimal as the initial teething problems related to the programme have been resolved. These issues included technical hitch in viral load (VL) testing procedures, a poor turn-around time for VL results, and poor pharmacy documentation. Excluded from this study were children whose relevant data of interest (as described previously) were missing. HIV-infected children older than 15 years of age were also seen at the adult ART clinic of FMC, Makurdi, and could not meet the population of this study.

2.4. TreatmentFollow-Up. We have previously described the HIV care and treatment protocol and the follow-up schedule for our HIV-infected children in our earlier publication [27]. In summary, HAART initiation was in accordance with the clinical and age-dependent immunological criteria of the World Health Organization (WHO) guidelines of 2006 and 2010. These guidelines were adopted in the Nigerian National Guidelines for Paediatric HIV and AIDS Treatment and Care [28, 29]. Trained nurses and adherence counselor provided counseling on HAART adherence to the children and their caregivers during each clinic visit. Co-trimoxazole (CTX) prophylaxis was provided to all subjects regardless of their CD4 count levels. In addition, children less than 2 years old with HIV-tuberculosis coinfection received HAART regardless of the CD4 count levels. The first-line HAART regimen was zidovudine (AZT) or stavudine (D4T) plus lamivudine (3TC) plus nevirapine (NVP) or efavirenz (EFZ) or lopinavir/ritonavir-LPV/r. The lopinavir/ritonavir-LPV/r was for subjects who had been exposed to NVP in the prevention of mother-to-child transmission of HIV attempts. The first-line HAART (commenced 2-8 weeks after antituberculous therapy) for children weighing less than 10 kg and/or those younger than 3 years of age having HIV-tuberculosis coinfection was a combination of triple nucleoside reverse transcriptase inhibitors (NRTIs) including zidovudine (AZT) plus 3TC plus abacavir (ABC).

AZT or D4T plus 3TC plus EFZ were prescribed for children with tuberculosis (TB) who were [greater than or equal to] 10 kg in weight or older than 3 years of age. Children who acquired TB while on 1st-line ART-incident TB (and who were previously on NVP-based regimen and less than 3 years of age or weighs less than 10 kg) had their ART regimen changed to triple NRTIs. If NVP was to be continued in HIV-TB coinfection, it was increased to the maximum dose of 200mg/[m.sup.2]. For subjects [greater than or equal to] 3 years or [greater than or equal to] 10 kg in weight who developed incident TB, EFV is given or the NVP is substituted with EFV. If the children were on LPV/r-based regimen, the antituberculous regimen would comprise rifabutin instead of rifampicin.

For children to qualify as having treatment failure on 1stline ART, they must have been on it for at least 24 weeks. For the regimen containing AZT or D4T plus 3TC plus NVP or EFV, the 2nd line regimen comprised ABC or didanosine (DDI) plus 3TC plus LPV/r, and the antituberculous regimen consisted of rifabutin instead of rifampicin. For children who had LPV/r as a 1st line ARV, the 2nd line ART comprised one new NRTI plus 3TC plus NVP or EFV or triple NRTIs. For subjects on triple NRTIs as 1st-line, the 2nd-line regimen contained at least one new NRTI plus 3TC plus NVP or EFV or LPV/r.

Isoniazid (INH), ethambutol (E), rifampicin (RMP), and pyrazinamide (Z) for 2 months, followed by INH and RMP for 4 months (for pulmonary TB) and 7 months (for extrapulmonary TB) was the standard TB treatment regimen. For TB re-treatment, the 8-month treatment regimen consisted of 2 months of streptomycin (S), INH, E, RMP, and Z; 1 month of RMP, INH, E, and Z; and 5 months of RMP, INH, and E.

Both intercurrent and opportunistic infections (OIs) were promptly treated. Ready-to-eat-therapeutic foods ("plumpy nuts"), as well as nutrition education, were administered to those recognized with undernutrition. The caregivers were also encouraged to be part of the HIV support group, especially for children who have not been attending clinics regularly or those being lost to follow-up [30].

2.5. Definitions of Cases. Prevalent TB was assumed among children having TB at the time of enrolment into care and before ART initiation.

Incident TB was when children acquired TB while on HAART. It is described as early incident TB-EITB when it occurs within first 6 months of ART. It is late incident TBLITB when TB acquisition occursafter the first 6 months of a 12-month follow-up period [27].

TB-immune reconstitution inflammatory syndrome (IRIS) was defined as incident TB occurring within the first 6 months of ART in association with good immunological recovery and viral suppression [28, 29].

Virological failure was defined as the HIV RNA becoming reproducibly detectable again after being "undetectable" (i.e., HIV RNA PCR <200 copies/ml) or HIV RNA not suppressed to undetectable levels after 6 months of therapy [28, 29].

The return of the CD4 count to pretherapy baseline or below, in the absence of other concurrent infection to explain the transient CD4 decrease, or a greater than 50% fall from peak levels of therapy of CD4 count in the absence of other concurrent infection to explain the transient CD4 decrease was defined as immunological failure [28, 29].

A high viral load was when HIV RNA copies >10,000 copies per millilitre of blood [27, 31].

The WHO age-dependent severe immunosuppression was defined when absolute CD4 count was <1500 cells/[mm.sup.3] in children less than 12 months, < 750 cells/[mm.sup.3] for children 12-35 months, < 350 cells/[mm.sup.3] for children 36-59 months, and < 200 cells/[mm.sup.3] for children [greater than or equal to] 59 months [28].

A lost to follow-up (LTFP) was defined as an instance where the child was not seen for three consecutive months from a scheduled visit date.

Anaemia is defined as haemoglobin concentration value less than 10 gram per deciliter [27].

The weight for height Z-score less than -2 standard deviations (SD) (from WHO reference median computed using the WHO Anthro software (version 2.0, 2008) based on the WHO child growth standards of 2006) defined undernutrition in children less than 5 years of age [32].

The body mass index (BMI) (calculated as the weight in kilograms divided by the square of the height in meters (kg/[m.sup.2])) values < 18.5 defined undernutrition in children >5 years [33].

2.6. Data Extraction. Data were abstracted from the electronic databases and the patients' record files (PRF). Missing data in the PRF were supplemented with data from the electronic databases and vice versa. Data abstracted included those of subjects' age, gender, anthropometric measurements, and other diagnosed comorbidities/opportunistic infections (oropharyngeal candidiasis, diarrheal disease, sepsis, pneumonia, anaemia, and hepatitis B and hepatitis C infections). Time-dependent factors (CD4 counts, the viral load, the haemoglobin value, and the anthropometric growth parameters) were extracted from the Clinical Evaluation Forms at the 6th month of follow-up for each subject. At the 6th and 12th month of follow-up, specific information obtained from the record were those related to prevalent TB, EITB, LITB, vital status state (dead or alive), children lost to follow-up, and children transferred to other health facilities. The cause of death was ascertained using the children's hospital records or by means of a verbal autopsy from family members when deaths were confirmed among children that missed scheduled clinic visit.

2.7. Statistical Analysis. The characteristics of the subjects at the commencement of HAART were summarized using means and medians (for continuous variables) and proportions (for categorical variables). Stratification of subjects' ages into 4 groups (< 12, 12-35, 36-59, and >59) was done in order to take advantage of the WHO age-dependent immunological grading for HIV-infected children [28]. The main outcome of the study was mortality occurring within the first 6 months (early) and after the first 6 months (late) on the 12 months of HAART follow-up. However, subjects with virological failures were also noted at 6 months and 12 months of HAART. The Kaplan-Meier method was used to assess the cumulative probability of early and late mortality occurring per 100 child-years observation. Subjects that were lost to follow-up, subjects that were transferred out to other ART programme, and subjects that were followed-up to the end of the study (December 2013) were censored for analysis. Associations of baseline factors (sociodemographics, CD4 counts, viral load, undernutrition, and comorbidities) with early mortality were tested for by Cox proportional hazards regression models and expressed for the hazard ratios and 95% confidence intervals. For late mortality, association with some time-dependent baseline factors modified/affected by ART exposure (i.e., the CD4 count, the viral load, the haemoglobin level, undernutrition and opportunistic infections), which were noted at 6 months of HAART follow-up were also tested using the Cox proportional hazards regression models. Factors with p values < 0.1 in bivariate analyses were tested at multivariate analyses. For all analyses, confidence intervals (CI) were set at 95% level and p values less than 0.05 were considered statistically significant. Statistical analysis was done using the SPSS version 20.

3. Results

3.1. Baseline Characteristics. Of the 408 children seen during the study period, only 368 were studied. Because of incomplete data, 40 children (9.8%) were excluded from the study. However, these 40 children did not differ significantly in baseline characteristics from the cohort that was studied. The 368 children ranged in age from 0.3 to 13 years. The median age was 5.63 years, and the interquartile range (IQR) was 3-8 years. The majority (57.1%) of the children were 5 years of age and above. There were 206 males (M) and 162 females (F) with a male to female ratio of 1: 0.8. At the commencement of HAART, the median CD4 count was 623.0 cells/[mm.sup.3] (IQR; 205-1067 cells/[mm.sup.3]), and the median viral load ([log.sub.10]) was 4.28 copies/ml (IQR; 3.79-5.11 copies/ml). Furthermore, there were 228 (61.9%) children with severe HIV disease (WHO Clinical stages 3 and 4), 213 (57.9%) with viral load [greater than or equal to] 10,000 copies/ml, 121 (32.9%) children with severe agedependent immunosuppression (i.e., late presenters), 73 (19.8%) children with tuberculosis (prevalent tuberculosis), and 64 (17.4%) with anaemia at baseline before HAART. There were also 210 (57.1%) undernourished children including 40 (10.9%) under-five children and 170 (46.2%) older children. Adverse reaction was seen in 3 children on EFV but none died.

Figure 1 is the schematic illustration of the follow-up of the subjects. Among the 368 HIV-infected children that were commenced on HAART, 81 per 100 child-years were followed up to 12 months of therapy. Retention in care and treatment was 89.7% at 6 months and 80.9% at 12 months of follow-up. The median time to HAART initiation was 31 days. There were 40 deaths, with 30 (30/368, 8.2%) occurring in the first 6 months and 10 (10/330, 3.0%) in the later months. There was a significant reduction in mortality rates from 17.3 deaths per 100 child-years at 6 months to 3.0 deaths per 100 child-years at 12 months of HAART (p < 0.01). The median time to mortality was 85 days within the first 6 months and 304 days after the first 6 months of HAART.

Table 1 shows the predictors of mortality among the children following 6 months exposure to highly active antiretroviral therapy. In the unadjusted Cox regression analyses, the risk of dying was more in HIV-infected children initiated on EFV-based HAART (cHR; 8.5, 95% CI; 3.360-21.578, p < 0.001) or three NRTIs HAART (cHR; 17.6, 95% CI; 7.173-43.069, p [less than or equal to] 0.001) compared to NVP-based HAART; those with tuberculosis (cHR; 10.4, 95% CI; 4.766-22.745, p [less than or equal to] 0.001); children with WHO stages 3 and 4 (cHR; 8.7, 95% CI; 2.073-36.531, p = 0.003); severe immunosuppression (cHR; 218, 95% CI; 6.322-7541.150, p = 0.003); and those with high viral load ([greater than or equal to]10,000 copies/ml) (cHR; 22.2, 95% CI; 3.026-163.111, p = 0.002). All the 21 patients with tuberculosis that died were diagnosed with the opportunistic infection at HAART initiation (i.e., prevalent tuberculosis). However, in the adjusted Cox regression, only children with high viral load remained a predictor of mortality at 6 months of HAART. The trend was such that the risk of dying in HIV-infected children with a high viral load (>10,000 copies/ml) was eighteen times more as compared to those with a less viral load (95% CI; 2.428-134.77, p = 0.005). The risk of dying was not dependent on baseline factors like age, gender, anaemia, and undernutrition.

Table 2 shows the predictors of mortality at 12 months of highly active antiretroviral therapy. In the unadjusted Cox regression analyses, the risk of dying was more in HIV-infected children on LPV/r-based second-line HAART (cHR; 7.9, 95% CI; 2.248-28.284, p = 0.001) compared to those still on NVPbased HAART, children who developed virological failure (cHR; 9.8, 95% CI; 2.789-35.088, p [less than or equal to] 0.001), and those with severe immunosuppression (cHR; 5.4, 95% CI; 1.523-19.139, p = 0.009) on HAART. The risk of death was lower in older children (>5 years of age) with undernutrition (cHR; 0.153, 95% CI; 0.038-0.611, p = 0.008). However, in the adjusted Cox regression, only those children with severe immunosuppression were at a higher risk of dying. The trend was that the risk of dying while on HAART in the first year of therapy in HIV-infected children with severe immunosuppression at or before 6 months of follow-up was 17 times more as compared to those without severe immunosuppression (95% CI; 3.844-77.700, p [less than or equal to] 0.001). The risk of dying at the 12 months of ART was not dependent on having or developing tuberculosis even when tuberculosis was seen in some of the children at death. Fortyfour children had a virological failure at 6 months of HAART, with a prevalence proportion of 14.3% (i.e., 85.7% had undetectable HIV-RNA copies). Out of these 44 children, 6 (6/44, 13.6%) had died before or at the end of 12 months of HAART. The mean age of the 6 children with virological failure that died was 12 years including 2 girls and 4 boys.

Table 3 illustrates the causes of deaths among the HIV-infected children within the 12 months period of follow-up on HAART. There were 40 deaths within a year of HAART with 30 and 10 deaths occurring within the first 6 months and the later 6 months, respectively. Most of the deaths in the first 6 months of HAART occurred in children with prevalent tuberculosis (21, 70%). Three under-five children who had sepsis and two other children died from severe pneumonia.

At the later 6 months of HAART, severe pneumonia (4, 40%) and incident tuberculosis (3, 30%) were the causes of mortality at the later phase of ART. Two of the four dead children with severe pneumonia were older than 5 years of age and they were also undernourished.

Seven children (4 in the first 6 months and 3 later) died at home with the caregivers only able to give "a history of febrile illness" before their demise.

4. Discussion

In this cohort of HIV-infected children that were followedup for one year, the majority, 89.7% and 80.9% were still on HIV care and treatment at 6 months and 12 months, respectively. The study also revealed a significant reduction in mortality rates from 17.3 deaths per 100 child-years (30 deaths) at 6 months to 3.0 deaths per 100 child-years (10 deaths) at 12 months of HAART.

This pattern of high mortality in the first 6 months followed by a dramatic decrease in death rate agrees with other studies [9,10], and it suggests that HIV-infected children require some time before the benefits of HAART are fully realized [9, 10]. Bearing in mind the approach to therapy at the time of this study (the intention to start HAART was dependent on clinical and age-dependent immunological criteria), it was impossible to salvage all the HIV-infected children. Furthermore, the number of such HIV's mortality may not decrease with HAART being initiated much later in the disease course. Similar trend was also noted by other researchers [9, 10].

In multivariate Cox regression analyses, mortality at 6 months of HAART in our cohort was dependent on having a high pretreatment viral load (>10,000 copies/ml), with the risk of dying being 18 times more; while, HIV-infected children still having severe immunosuppression at/or before 6 months of ART are 17 times more likely to die before the 12 months of HAART.

The mortality rate of 3.0 deaths per 100 child-years in this study is lower than the rates of 4.0, 4.7, and 8.4 per 100 childyears reported in Ethiopia [7], South Africa [8], and Kenya [6]; but it is higher than the rates in other Nigerian studies which reported 1.0 death per 100 child-years and 2.67 deaths per 100 child-years in Jos [24] and Lagos, respectively [26].

Outside Africa, the mortality rate of 3.0 deaths per 100 child-years in this study is higher than the 2.0 reported in the United Kingdom [16] and the 2.31 per 100-child years in China [34].

While studies in Africa on HIV-related mortality are complex because of other significant non-HIV causes of mortality [3-11, 24], we suggest the following factors to be responsible for the relative good survival in the present cohort who presented mostly (61.9%) with severe HIV disease (WHO stages 3 or 4) and (57.9%) with viral load [greater than or equal to]10,000 copies/ml.

Firstly, the good training and retraining on paediatric HIV care and treatment received by the healthcare providers caring for these children from the Harvard PEPFAR programme may have impacted positively on the supportive care given to these children. Secondly, a robust ART adherence support group (i.e., the kiddies' club) in our ART programme which engages parents/caregivers in ensuring an optimal ART adherence among the children [30]. Thirdly, the fact that all the children less than 24 months of life were commenced on HAART regardless of their CD4+ cell counts, in line with the Nigerian Guidelines of paediatric ART of 2010 [29]. The fifth reason is that all the HIV-infected children in this cohort were placed on CTX prophylaxis regardless of their CD4 counts. The role of CTX prophylaxis in reducing morbidity and mortality in HIV-infected children has been confirmed by other studies [24, 35]. And lastly, the children commenced HAART at a relatively high median CD4 count of 623.0 cells/[mm.sup.3] compared to the Jos [24], South African [8] and Kenyan [6] studies with a lower baseline median CD4 counts of 480 cells/[mm.sup.3], 226 cells/[mm.sup.3], and 286 cells/[mm.sup.3], respectively.

In this study, having a high viral load (>10,000 copies/ml) at baseline increases the risk of dying in the early phase of HAART by 18 times compared to when individuals start HAART at lower values. This increased risk of death with a high viral load exists regardless of the types of HAART regimen, whether the children were infected with tuberculosis or not, the WHO clinical stage, and the degree of immunosuppression, all of which appear to impact on mortality at an unadjusted Cox regression analysis.

Specifically, in the study by Wang et al. among Chinese adults (16-80 years old), patients having VL > 10,000 copies/ml and HIV-drug resistance were two times as likely to die compared to patients with VL < 1,000 copies/ml [36]. Furthermore, individuals with VL [greater than or equal to] 10,000 copies/ml and without HIV-drug resistance were also 1.7 times as likely to die [36]. Although we did not test for HIV resistance in our cohorts with a high pretreatment viral load, HIV-drug resistance in ART-naive individuals with high viral load was suggested as the reason for the increased mortality in the study of Wang et al. [36]. While Hogg et al. [37] and Zaccarelli et al. [38] also reported a high mortality in their patients with drug-resistant HIV infection with a high viral load, two other studies did not find same [39, 40].

Boosted protease inhibitors (Boosted PI) are often used in 2nd line HAARTregimen because they are associated with multiple clinical benefits, including higher efficacy against resistant HIV strains [41] and a lack of PI-associated resistance mutations in treatment-naive patients [42]; unexpectedly, our study revealed that at unadjusted Cox regression, our children on LPV/r-based second-line HAART tend to die more when compared to those still on NVP-based HAART at 6 months of therapy. We suggest that the children that died on LPV/r were commenced rather late on it (mean age at death was 12 years), had developed resistance to it, or may have had a suboptimal adherence to it.

Within the first 6 months of ART, children on EFV-based or three-NRTI HAART compared to NVP-based HAART, those coinfected with tuberculosis, children with severe HIV disease (WHO stages 3 and 4), and children with severe immunosuppression are also associated with higher mortality, albeit at unadjusted Cox analyses. After the first 6 months, the risk of dying was also more in children who developed virological failure, also at unadjusted Cox analyses.

Worthy to note is the fact that all the children who died on EFV-based HAART and three-NRTI HAART were also coinfected with tuberculosis.

Similar trends in mortality with HIV/tuberculosis coinfection, severe HIV disease (WHO stages 3 and 4), virological failure, and severe immunosuppression have been noted in numerous studies [43-47], thereby providing a focus for targeted management of high-risk HIV-infected children at risk of dying [47].

In this study, the risk of dying while on HAART in the first year of therapy in children with severe immunosuppression was 17 times more when compared to those without severe immunosuppression. In other words, HIV-infected children who fail to achieve CD4+ T cells recovery at 6 months of ART are at risk of dying before and or at 12 months of HAART. Thus, even in advanced HIV disease or in children with virological failure, the reconstitution of the immune system induced by HAART is due to an increase in the activation of the naive CD4+ T cell of thymic origin [48]. This immune system restoration thereafter supports the normalization of immune parameters (cytokine production, lymphoproliferative response, and immunoglobulin levels in plasma), with the recovery of naive [CD4.sup.+] T cells occurring more rapidly if treatment is started at a younger age [48]. When [CD4.sup.+] T recovery does not happen, associated comorbidity from opportunistic infections like tuberculosis and life-threatening bacterial infections contribute to mortality [24].

As most of the children that died in this cohort had a dual HIV-tuberculosis coinfections (21/30, 70% of deaths in the first 6 months; 3/10, 30% in later months), tuberculosis was not found to be associated with mortality at multivariate Cox analysis. However, HIV-infected children had been known to demonstrate greater mortality from tuberculosis, with mortality as high as 20-35% in RLC [49-51]. In actual fact, all children who have dual HIVtuberculosis infections at the time of their deaths are internationally classified as having died from HIV [52].

Severe undernutrition in HIV-infected children usually results in marked depression of both cell-mediated and humoral immunity reducing their ability to cope with lifethreatening infections [30, 31]. In addition, micronutrient deficiencies may decrease the effectiveness of ART among undernourished individuals [53].

Neither undernutrition nor anaemia is a predictor of mortality in this study in contrast to what was reported in other studies [6, 9, 10, 54-56]. Incidentally, the risk of death was lower in older undernourished children (>5 years of age) among whom two of the four dead children also had severe pneumonia. Bacterial infections, pneumonia, and tuberculosis were the main causes of mortality in this study. A similar trend had been observed by two previous studies [6, 14]. While the causes of death in children that died outside the hospital were unknown, verbal autopsy from their caregivers was that of a "brief febrile illness" also, in keeping with a possible infectious cause.

The risk of death also did not depend on age or gender in this study. This contrasts with the study by Ebonyi et al. [24] whereby the risk of dying was about three and half times more in children <5 years compared to those >5 years. Also, in the study by Bolton-Moore et al. in Zambia, age was found to be a determinant of mortality as the median age of children on ART who died was 46 months [9]. In South Africa, Zanoni et al. also reported that female gender was associated with an increased risk of HIV-mortality in children initiated on ART [8]. In a North American study, Foca et al. also reported a higher mortality in female HIVinfected children [57]. However, Zanoni et al. concluded by saying that they were unsure if the gender-related HIVmortality was as a result of biological differences between the genders [8]. Reasons put forward to explain the higher mortality in female gender included gender-related discriminations that make parents delay bringing female children to care, as parents pay more societal values on their male children in South Africa [8].

5. Limitations of the Study

Being a retrospective study, the small sample size may have reduced the precision and the observed effect sizes of some variables (i.e., HAART regimens, tuberculosis, WHO clinical stage, virological failure, and undernutrition) in detecting a difference at multivariate Cox regression analyses. In addition, the small events (30 and 10 deaths before, and after 6 months of HAART) may have limited the power of assessing the significance of aforementioned variables in multivariate analyses.

Also, adherence to ART is an important factor in treatment success, but we assessed adherence using self-report information from the caregivers. The reliability for accurate true adherence is therefore limited.

It is also conceivable that some children that were lost to follow-up had actually died, which might have affected both the validity and precision of our estimate as pointed out by an earlier systemic analysis done in 2009 [58]. However, a recent systemic review in 2017 suggests that more of sub-Saharan HIV-infected patients that are lost to follow-up are surviving better [59]. Also, the lack of postmortem studies in our program and the reliance on the verbal autopsy for children that died at home may have led to an inaccurate labeling of the cause of death in such cases. We also could not do genotypic resistance testing among our children with virological failure at the time the study was conducted.

Regardless of these limitations, this study is strengthened by the fact that time-dependent baseline factors modified/affected by ART exposure (i.e., the CD4 count, the viral load, the haemoglobin level, under-nutrition, and opportunistic infections) were accounted for in the analysis of mortality over the duration of 12 months therapy. Also, there was no HAART discontinuation in any of our cohorts which have allowed for the intent-to-treat assumption and reliable interpretations of HAART effect. However, caution should be applied in the generalization of the findings of this study as its small sample size may have had a profound effect on the power to independently detect the significance of some known predictors (HAART regimens, tuberculosis, WHO clinical stage, virological failure, and undernutrition) of mortality in HIV infection at multivariate analysis.

6. Conclusions

This study has shown that the initial high mortality seen in the first 6 months of HAART was significantly reduced before the end of 12 months of ART. It suggests a high baseline viral load and severe immunosuppression, as the independent predictors of mortality in the early and late phase of HAART, respectively. This knowledge should allow for a thorough targeted early initiation of HAART for these HIV-infected children who are at a higher risk of dying.

This recommendation would be in conformity with the 90-90-90 targets for identifying HIV-infected children, bringing them to care, initiating ART, and retaining them in care in order to achieve a sustained virologic suppression [60].

In addition, other measures that have been proven to reduce mortality in severely immunocompromised HIVinfected individuals initiating ART in Africa can also reduce further the mortality seen in our setting, and can also be applied [61,62]. These measures include the use of ready-to-use supplementary food (RUSF) and an enhanced anti-infection prophylaxis (EAIP). The EAIP comprises trimethoprim sulfamethoxazole plus 12 weeks of isoniazid-pyridoxine, 12 weeks of fluconazole, 5 days of azithromycin, and a single dose of albendazole against mortality from tuberculosis, cryptococcal infection, oral/oesophageal candidiasis, and severe bacterial infections [61, 62].

Data Availability

The caregivers and parents of children and the children included in this evaluation had not consented to sharing of their patient-level data, and for us to do so would be a violation of their privacy. As such, due to issues with patient confidentiality, the patient-level data on which the analyses were based cannot be posted in a public forum.

https://doi.org/ 10.1155/2018/6409134

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Joint United Nations Programme on HIV/AIDS (UNAIDS), "Progress report on the global plan towards the elimination of new HIV infections among children and keeping their mothers alive," 2015, http://www.unaids.org/sites/default/ files/media_asset/JC2774_2015ProgressReport_GlobalPlan_ en.pdf.

[2] Progress Report on the Global Plan-UNAIDS, 2014, http:// www.unaids.org/sites/default/files/documents/JC2681_2014Global-Plan-progress_en.pdf.

[3] F. Dabis, N. Elenga, N. Meda et al., "18-Month mortality and perinatal exposure to zidovudine in West Africa," AIDS, vol. 15, no. 6, pp. 771-779, 2001.

[4] D. Dunn and HIV Paediatric Prognostic Markers Collaborative Study Group, "Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis," The Lancet, vol. 362, no. 9396, pp. 1605-1611, 2003.

[5] R. Spira, P. Lepage, P. Msellati et al., "Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group," Paediatrics, vol. 104, no. 5, p. e56, 1999.

[6] D. C. Wamalwa, E. M. Obimbo, C. Farquhar et al., "Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort," BMC Pediatrics, vol. 10, no. 1, p. 33, 2010.

[7] D. N. Koye, T. A. Ayele, and B. M. Zeleke, "Predictors of mortality among children on antiretroviral therapy at a referral hospital, Northwest Ethiopia: a retrospective follow up study," BMC Pediatrics, vol. 12, no. 1, p. 161, 2012.

[8] B. C. Zanoni, T. Phungula, H. M. Zanoni, H. France, and M. E. Feeney, "Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa," PLoS One, vol. 6, no. 7, article e22706, 2011.

[9] C. Bolton-Moore, M. Mubiana-Mbewe, R. A. Cantrell et al., "Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia," JAMA, vol. 298, no. 16, pp. 1888-1899, 2007.

[10] C. N. Bong, J. K. Yu, H. C. Chiang et al., "Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi," AIDS, vol. 21, no. 13, pp. 1805-1810, 2007.

[11] A. Reddi, S. C. Leeper, A. C. Grobler et al., "Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa," BMC Pediatrics, vol. 7, no. 1, p. 13, 2007.

[12] F. Rouet, P. Fassinou, A. Inwoley et al., "Long-term survival and immuno-virological response of African HIV-1- infected children to highly active antiretroviral therapy regimens," AIDS, vol. 20, no. 18, pp. 2315-2319, 2006.

[13] C. G. Sutcliffe, J. H. van Dijk, B. Munsanje et al., "Risk factors for pre-treatment mortality among HIV-infected children in rural Zambia: a cohort study," PLoS One, vol. 6, no. 12, article e29294, 2011.

[14] R. M. Viani, M. R. Araneta, J. G. Deville, and S. A. Spector, "Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy," Clinical Infectious Diseases, vol. 39, no. 5, pp. 725-731, 2004.

[15] S. L. Gortmaker, M. Hughes, J. Cervia et al., "Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1," New England Journal of Medicine, vol. 345, no. 21, pp. 1522-1528, 2001.

[16] D. M. Gibb, T. Duong, P. A. Tookey et al., "Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland," BMJ, vol. 327, no. 7422, p. 1019, 2003.

[17] N. Workneh, T. Girma, and M. Woldie, "Immunologic and clinical outcomes of children on HAART; a retrospective cohort analysis at Jimma University Specialized Hospital," Ethiopian Journal of Health Sciences, vol. 19, no. 2, pp. 75-82, 2009.

[18] Nigeria Operational Plan Report, 2013, https://www.pepfar. gov/documents/organization/222176.pdf.

[19] E. A. Anigilaje, B. R. Ageda, and N. O. Nweke, "Barriers to uptake of prevention of mother-to-child transmission of HIV services among mothers of vertically infected HIV-seropositive infants in Makurdi, Nigeria," Patient Preference and Adherence, vol. 2016, no. 10, pp. 57-72, 2016.

[20] Guidelines for Using Antiretroviral Agents Among HIV-Infected Adults and Adolescents, Recommendations of the Panel on Clinical Practices for Treatment of HIV, https:// www.cdc.gov/mmwr/preview/mmwrhtml/rr5107a1.htm.

[21] A. Edmonds, M. Yotebieng, J. Lusiama et al., "The effect of highly active antiretroviral therapy on the survival of HIV infected children in a resource-deprived setting: a cohort study," PLoS Medicine, vol. 8, no. 6, p. e1001044, 2011.

[22] W. T. Shearer, T. C. Quinn, P. LaRussa et al., "Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group," New England Journal of Medicine, vol. 336, no. 19, pp. 1337-1342, 1997.

[23] A. P. Kourtis, C. Ibegbu, A. J. Nahmias et al., "Early progression of disease in HIV-infected infants with thymus dysfunction," New England Journal of Medicine, vol. 335, no. 19, pp. 1431-1436, 1996.

[24] A. O. Ebonyi, S. Oguche, S. T. Meloni et al., "Predictors of mortality in a clinic cohort of HIV-1 infected children initiated on antiretroviral therapy in Jos, Nigeria," Journal of AIDS and Clinical Research, vol. 5, no. 12, p. 403, 2014.

[25] A. C. Ubesie, K. K. Iloh, C. A. Ayuk, S. N. Ibeziako, J. I. Emodi, and I. Obumneme-Anyim, "Outcomes of Paediatrics HIV care at the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu after ten years of service," Nigerian Journal of Paediatrics, vol. 44, no. 1, pp. 22-25, 2017.

[26] M. A. Ojeniran, A. Emokpae, C. Mabogunje, P. Akintan, M. Hoshen, and R. Weiss, "How are children with HIV faring in Nigeria?- a 7 year retrospective study of children enrolled in HIV care," BMC Pediatrics, vol. 15, no. 1, p. 87, 2015.

[27] E. A. Anigilaje, S. A. Aderibigbe, A. O. Adeoti, and N. O. Nweke, "Tuberculosis, before and after antiretroviral therapy among HIV-infected children in Nigeria: what are the risk factors?," PLoS One, vol. 11, no. 5, article e0156177, 2016.

[28] Federal Ministry of Health, National Guidelines for Paediatric HIV and AIDS Treatment and Care, Federal Ministry of Health, Abuja, Nigeria, 2007, http://www.who.int/hiv/amds/ Nigeria_paediatric_2007.pdf.

[29] Federal Ministry of Health, National Guidelines for Paediatric HIV and AIDS Treatment and Care, Federal Ministry of Health, Abuja, Nigeria, 2010, http://preventcrypto.org/wp-content/uploads/2015/ 10/NigeriaPaediatricARTguidelines20101369045239.pdf.

[30] E. A. Anigilaje, O. J. Dabit, R. K. Tyovenda et al., "Effects of leisure activities and psychosocial support on medication adherence and clinic attendance among children on antiretroviral therapy," HIV/AIDS--Research and Palliative Care, vol. 6, p. 127, 2014.

[31] S. T. Meloni, C. A. Chang, G. Eisen et al., "Long-term outcomes on antiretroviral therapy in a large scale-up program in Nigeria," PLoS One, vol. 11, no. 10, article e0164030, 2016.

[32] World Health Organization, Anthro for Personal Computers, Version 3.2.2, 2011. Software for Assessing the Growth and Development of the World's Children, Child Growth Standards, World Health Organization, Geneva, Switzerland, 2011, http://www.who.int/childgrowth/software/anthro_pc_manual_ v322.pdf.

[33] World Health Organization, Physical Status: The Use and Interpretation of Anthropometry, Report of a WHO Expert Committee. WHO Technical Report Series 854, World Health Organization, Geneva, Switzerland, 1995, http://whqlibdoc. who.int/trs/WHO_TRS_854.pdf?ua=1.

[34] Y. Zhao, C. Li, X. Sun et al., "Mortality and treatment outcomes of China's National Pediatric antiretroviral therapy program," Clinical Infectious Diseases, vol. 56, no. 5, pp. 735-744, 2013.

[35] C. Chintu, G. J. Bhat, A. S. Walker et al., "Co-trimoxazole as prophylaxis against opportunistic infections in HIV infected Zambian children (CHAP): a double-blind randomised placebocontrolled trial," The Lancet, vol. 364, no. 9448, pp. 1865-1871, 2004.

[36] X. Wang, H. Xing, Y. Ruan et al., "Effect of viral load and drug resistance on mortality among Chinese HIV-infected patients receiving antiretroviral treatment," Journal of Antivirals and Antiretrovirals, vol. 4, no. 3, pp. 060-059, 2012.

[37] R. S. Hogg, D. R. Bangsberg, V. D. Lima et al., "Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART," PLoS Medicine, vol. 3, no. 9, p. e356, 2006.

[38] M. Zaccarelli, V. Tozzi, P. Lorenzini et al., "Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort ofHIV-infected patients," AIDS, vol. 19, no. 10, pp. 1081-1089, 2005.

[39] M. A. Recsky, Z. L. Brumme, K. J. Chan et al., "Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy," Journal of Infectious Diseases, vol. 190, no. 2, pp. 285292, 2004.

[40] G. M. Lucas, J. E. Gallant, and R. D. Moore, "Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing," AIDS, vol. 18, no. 11, pp. 1539-1548, 2004.

[41] S. Abgrall, X. Duval, V. Joly et al., "Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy," Clinical Infectious Diseases, vol. 37, no. 11, pp. 1517-1526, 2003.

[42] D. J. Kempf, M. S. King, B. Bernstein et al., "Incidence of resistance in a double-blind study comparing lopinavir/ ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine," Journal of Infectious Diseases, vol. 189, no. 1, pp. 51-60, 2004.

[43] S. F. Callens, N. Shabani, J. Lusiama et al., "Mortality and associated factors after initiation of paediatric antiretroviral treatment in the Democratic Republic of the Congo," Pediatric Infectious Disease Journal, vol. 28, no. 1, pp. 35-40, 2009.

[44] M. Mubiana-Mbewe, C. Bolton-Moore, Y. Banda et al., "Causes of morbidity among HIV-infected children on antiretroviral therapy in primary care facilities in Lusaka, Zambia," Tropical Medicine and International Health, vol. 14, no. 10, pp. 1190-1198, 2009.

[45] J. Van Griensven, L. De Naeyer, J. Uwera, A. Asiimwe, C. Gazille, and T. Reid, "Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/ nurse-based care," BMC Pediatrics, vol. 8, no. 1, p. 39, 2008.

[46] C. G. Sutcliffe, J. H. van Dijk, C. Bolton, D. Persaud, and W. J. Moss, "Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa," Lancet Infectious Diseases, vol. 8, no. 8, pp. 477-489, 2008.

[47] M. M. Morsheimer, A. Dramowski, H. Rabie, and M. F. Cotton, "Paediatric ART outcomes in a decentralised model of care in Cape Town, South Africa," Southern African Journal of HIV Medicine, vol. 15, no. 4, pp. 148-153, 2014.

[48] S. Resino, I. Galan, A. Perez et al., "HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy," Clinical and Experimental Immunology, vol. 137, no. 3, pp. 570-577, 2004.

[49] A. Kouakoussui, P. Fassinou, M. F. Anaky et al., "Respiratory manifestations in HIV-infected children pre- and postHAART in Abidjan, the Ivory Coast," Paediatric Respiratory Reviews, vol. 5, no. 4, pp. 311-315, 2004.

[50] E. Walters, M. F. Cotton, H. Rabie, H. S. Schaaf, L. O. Walters, and B. J. Marais, "Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy," BMC Pediatrics, vol. 8, no. 1, 2008.

[51] A. Edmonds, J. Lusiama, S. Napravnik, F. Kitetele, A. Van Rie, and F. Behets, "Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children," International Journal of Epidemiology, vol. 38, no. 6, pp. 1612-1621, 2009.

[52] TB in Children-Getting, Diagnosing & Preventing TB-TB Facts, https://www.tbfacts.org/tb-children/.

[53] A. J. De Baets, J. Ramet, P. Msellati, and P. Lepage, "The unique features of pediatric HIV-1 in sub-Saharan Africa," Current HIV Research, vol. 6, no. 4, pp. 351-362, 2008.

[54] M. Marazzi, G. Liotta, P. Germano et al., "Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings," AIDS Research and Human Retroviruses, vol. 24, no. 4, pp. 555-560, 2008.

[55] M.-F. Anaky, J. Duvignac, L. Wemin et al., "Scaling up antiretroviral therapy for HIV-infected children in Cote d'Ivoire: determinants of survival and loss to programme," Bulletin of the World Health Organization, vol. 88, no. 7, pp. 490-499, 2010.

[56] A. F. Auld, M. Z. Tuho, K. A. Ekra et al., "Temporal trends in mortality and loss to follow-up among children enrolled in Cote d'Ivoire's national antiretroviral therapy program," Pediatric Infectious Disease Journal, vol. 33, no. 11, pp. 1134-1140, 2014.

[57] M. Foca, J. Moye, C. Chu et al., "Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV," Pediatrics, vol. 118, no. 1, pp. 146-155, 2006.

[58] M. W. Brinkhof, M. Pujades-Rodriguez, and M. Egger, "Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis," PLoS One, vol. 4, article e5790, 2009.

[59] K. Zurcher, A. Mooser, N. Anderegg et al., "Outcomes of HIV-positive patients lost to follow-up in African treatment programmes," Tropical Medicine and International Health, vol. 22, no. 4, pp. 375-387, 2017.

[60] M. A. Davies and J. Pinto, "Targeting 90-90-90--don't leave children and adolescents behind," Journal of the International AIDS Society, vol. 18, no. 7, p. 20745, 2015.

[61] F. A. Post, A. J. Szubert, A. J. Prendergast et al., "Reduction of early mortality in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team," Clinical Infectious Diseases, vol. 66, no. 2, pp. S132-S139, 2018.

[62] J. Mallewa, A. J. Szubert, P. Mugyenyi et al., "Effect of readyto-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallelgroup, randomised controlled trial," The Lancet, vol. 5, no. 5, pp. e231-e240, 2018.

Emmanuel Ademola Anigilaje (1) and Sunday Adedeji Aderibigbe (2)

(1) Department of Paediatrics, College of Health Sciences, University of Abuja, Abuja, Nigeria

(2) Department of Community Medicine, University of Ilorin, Ilorin, Kwara State, Nigeria

Correspondence should be addressed to Emmanuel Ademola Anigilaje; demolaanigilaje@yahoo.co.uk

Received 14 January 2018; Revised 15 April 2018; Accepted 2 May 2018; Published 19 June 2018

Academic Editor: Lucia Lopalco

Caption: Figure 1: Schematic diagram of the follow-up of the children over 12 months of highly active antiretroviral therapy. *17.3 deaths per 100 child-years; (#) 3.0 deaths per 100 child-years. ART = antiretroviral therapy, PrevTb = prevalent tuberculosis, ITB = Incident tuberculosis, and TFP = lost to follow-up.
Table 1: Predictors of mortality at 6 months of highly active
antiretroviral therapy.

Clinical variables              Mortality   No mortality

Baseline demography
Age (months)
  <12                           10 (31.2)    22 (68.8)
  12-35                         16 (28.6)    40 (71.4)
  36-59                          4 (6.1)     62 (93.9)
  >59 (ref)                      0 (0.0)    206 (100.0)
Gender
  Female                        12 (7.4)     150 (92.6)
  Male (ref)                    18 (9.1)     180 (90.9)
HAART regimens on enrolment
  EFV based                     10(21.7)     36 (78.3)
  ABC/3TC/AZT or D4T            12 (42.9)    16 (57.1)
  NVP based                      8 (2.8)     278 (97.2)
Prevalent TB at enrolment
  Yes                           21 (28.8)    52 (71.2)
  No (ref)                       9 (3.1)     276 (93.2)
Baseline clinical/laboratory
  findings
WHO clinical staging
  3 and 4                       28 (12.6)    194 (87.4)
  1 and 2 (ref)                  2 (1.4)     136 (98.6)
CD4 count
  Severe immunosuppression
    Yes                         30 (25.2)    89 (74.8)
    No (ref)                     0 (0.0)     241 (100)
Viral load (copies/ml)
  [greater than or equal        29 (13.7)    182 (86.3)
     to] 10,000
  <10,000 (ref)                  1 (0.7)     148 (99.3)
Anaemia (<8g/dl)
  Yes                            2 (3.2)     60 (96.8)
  No (ref)                      28 (9.4)     270 (90.6)
WHZ
  <-2 SD                        6 (15.0)     34 (85.0)
  [greater than or equal        24 (21.1)    90 (78.9)
     to] 2 SD (ref)
BMI
  <18.5                          0 (0.0)    166 (100.0)
  [greater than or equal         0 (0.0)      40 (100)

Clinical variables                       Bivariate analysis
                                   cHR          95% CI       p value
Baseline demography
Age (months)
  <12                           274060.24         --          0.840
  12-35                         274243.21         --          0.840
  36-59                         47987.49          --          0.862
  >59 (ref)                        --             --            --
Gender
  Female                          0.806      0.388-1.673      0.562
  Male (ref)                       --             --            --
HAART regimens on enrolment
  EFV based                       8.515      3.360-21.578     0.001
  ABC/3TC/AZT or D4T             17.577      7.173-43.069     0.001
  NVP based                        --             --            --
Prevalent TB at enrolment
  Yes                            10.412      4.766-22.745     0.001
  No (ref)                         --             --            --
Baseline clinical/laboratory
  findings
WHO clinical staging
  3 and 4                         8.702      2.073-36.531     0.003
  1 and 2 (ref)                    --             --            --
CD4 count
  Severe immunosuppression
    Yes                          218.350    6.322-7541.150    0.003
    No (ref)                       --             --            --
Viral load (copies/ml)
  [greater than or equal         22.217     3.026-163.111     0.002
     to] 10,000
  <10,000 (ref)                    --             --            --
Anaemia (<8g/dl)
  Yes                             0.327      0.078-1.374      0.127
  No (ref)                         --             --            --
WHZ
  <-2 SD                          0.731      0.299-1.788      4.492
  [greater than or equal           --             --            --
     to] 2 SD (ref)
BMI
  <18.5                           1.00      0.001-1904.991     1.00
  [greater than or equal           --             --            --

Clinical variables                    Multivariate analysis
                                 aHR        95% CI      p value
Baseline demography
Age (months)
  <12                             --          --          --
  12-35                           --          --          --
  36-59                           --          --          --
  >59 (ref)                       --          --          --
Gender
  Female                          --          --          --
  Male (ref)                      --          --          --
HAART regimens on enrolment
  EFV based                     1.963    0.462-8.332     0.361
  ABC/3TC/AZT or D4T            2.104    0.580-7.629     0.258
  NVP based                       --          --          --
Prevalent TB at enrolment
  Yes                           1.444    0.420-4.963     0.560
  No (ref)                        --          --          --
Baseline clinical/laboratory
  findings
WHO clinical staging
  3 and 4                       1.863    0.365-9.508      --
  1 and 2 (ref)                   --          --          --
CD4 count
  Severe immunosuppression
    Yes                         137813                   0.875
    No (ref)                      --          --          --
Viral load (copies/ml)
  [greater than or equal        18.089   2.428-134.77    0.005
     to] 10,000
  <10,000 (ref)                   --          --          --
Anaemia (<8g/dl)
  Yes                             --          --          --
  No (ref)                        --          --          --
WHZ
  <-2 SD                          --          --          --
  [greater than or equal          --          --          --
     to] 2 SD (ref)
BMI
  <18.5                           --          --          --
  [greater than or equal          --          --          --

     to] 18.5 (ref)

Ref = referenced variable; TB = tuberculosis; cHR = crude hazard
ratio; aHR = adjusted hazard ratio; 95% CI = 95% confidence
interval; NVP = nevirapine; EFV = efavirenz; LPV-r = lopinavir-
ritonavir; ABC = abacavir; 3TC = lamivudine; AZT = zidovudine;
d4T = starvudine; HAART = highly active antiretroviral therapy;
WHO = World Health Organization; WHZ = weight for health Z score;
BMI = body mass index; (#) 2006 WHO age-dependent immunological
criteria dichotomized into Yes or No for severe
immunosuppression.

Table 2: Predictors of mortality at 12 months of highly active
antiretroviral therapy.

Clinical variables                Mortality   No mortality

Baseline demography
Age (months)
  <12                               0(0)        22 (100)
  12-35                            2 (5.6)     34 (94.4)
  36-59                             0 (0)        58 (0)
  >59 (ref)                        8 (4.2)     184 (95.8)
Gender
  Female                           4 (2.9)     134 (97.1)
  Male (ref)                       6 (3.5)     164 (96.5)
HAART regimens at 6 month
  EFV based                         0 (0)       48 (100)
  LPV/r based                     6 (13.6)     38 (86.4)
  ABC/3TC/AZT or D4T                0 (0)       2 (100)
  NVP based                        4 (1.9)     210 (98.1)
Incident TB
  Yes                              3 (8.3)     33 (91.4)
  No (ref)                         7 (2.6)     265 (97.4)
Virological failure within
    first 6 months
  Yes                             6 (13.6)     38 (86.4)
  No (ref)                         4 (1.5)     260 (98.5)
WHO clinical staging
  3 and 4                          4 (2.2)     178 (97.8)
  1 and 2 (ref)                    6 (4.8)     120 (95.2)
Laboratory response to HAART
  at 6 months
CD4 count at 6 months
  Severe immunosuppression
    Yes                            6 (8.6)     64 (91.4)
    No (ref)                       4 (1.7)     234 (98.3)
Anaemia (<8g/dl) at 6 months
  Yes                              2 (5.0)     38 (95.0)
  No (ref)                         8 (3.0)     260 (97.0)
Anthropometric response to
  HAART at 6 months
WHZ at 6 months
  <-2 SD                            0(0)        2 (100)
  [greater than or equal           2 (1.8)     112 (98.2)
     to] 2 SD (ref)
BMI at 6 months
  <18.5                            4 (2.4)     162 (97.6)
  [greater than or equal          4 (15.4)     22 (84.6)
     to] 18.5 (ref)

                                       Bivariate analysis

Clinical variables                 cHR       95% CI      p value

Baseline demography
Age (months)
  <12                             0.000        --         0.987
  12-35                           1.309   0.278-6.163     0.734
  36-59                           0.000        --         0.980
  >59 (ref)                        --          --           --
Gender
  Female                          0.834   0.235-2.954     0.778
  Male (ref)                       --          --           --
HAART regimens at 6 month
  EFV based                       0.000        --         0.984
  LPV/r based                     7.975   2.248-28.284    0.001
  ABC/3TC/AZT or D4T              0.000        --         0.997
  NVP based                        --          --           --
Incident TB
  Yes                             1.314   0.279-6.190     0.729
  No (ref)                         --          --           --
Virological failure within
    first 6 months
  Yes                             9.892   2.789-35.088    0.001
  No (ref)                         --          --           --
WHO clinical staging
  3 and 4                         0.450   0.127-1.594     0.216
  1 and 2 (ref)                    --          --           --
Laboratory response to HAART
  at 6 months
CD4 count at 6 months
  Severe immunosuppression
    Yes                           5.40    1.523-19.139    0.009
    No (ref)                       --          --           --
Anaemia (<8g/dl) at 6 months
  Yes                             1.631   0.346-7.683     0.536
  No (ref)                         --          --           --
Anthropometric response to
  HAART at 6 months
WHZ at 6 months
  <-2 SD                          0.000        --         0.987
  [greater than or equal           --          --           --
     to] 2 SD (ref)
BMI at 6 months
  <18.5                           0.153   0.038-0.611     0.008
  [greater than or equal           --          --           --
     to] 18.5 (ref)

                                    Multivariate analysis

Clinical variables              aHR       95%CI       p value

Baseline demography
Age (months)
  <12                           --          --          --
  12-35                         --          --          --
  36-59                         --          --          --
  >59 (ref)                     --          --          --
Gender
  Female                        --          --          --
  Male (ref)                    --          --          --
HAART regimens at 6 month
  EFV based                    0.024   0.000-576.64    0.470
  LPV/r based                  1379         --         0.952
  ABC/3TC/AZT or D4T           4.143        --         0.987
  NVP based                     --          --          --
Incident TB
  Yes                           --          --          --
  No (ref)                      --          --          --
Virological failure within
    first 6 months
  Yes                          167.9        --         0.941
  No (ref)                      --          --          --
WHO clinical staging
  3 and 4                       --          --          --
  1 and 2 (ref)                 --          --          --
Laboratory response to HAART
  at 6 months
CD4 count at 6 months
  Severe immunosuppression
    Yes                        17.28   3.844-77.700    0.001
    No (ref)                    --          --          --
Anaemia (<8g/dl) at 6 months
  Yes                           --          --          --
  No (ref)                      --          --          --
Anthropometric response to
  HAART at 6 months
WHZ at 6 months
  <-2 SD                        --          --          --
  [greater than or equal        --          --          --
     to] 2 SD (ref)
BMI at 6 months
  <18.5                        0.001   0.000-6.223     0.120
  [greater than or equal        --          --          --
     to] 18.5 (ref)

Ref = referenced variable; TB = tuberculosis; cHR = crude hazard
ratio; aHR = adjusted hazard ratio; 95% CI = 95% confidence
interval; NVP = nevirapine; EFV = efavirenz; LPV-r = lopinavir-
ritonavir; ABC = abacavir; 3TC = lamivudine; AZT = zidovudine;
d4T = starvudine; HAART = highly active antiretroviral therapy;
WHO = World Health Organization; WHZ = weight for health Z-
score; BMI = body mass index; #2006 WHO age-dependent
immunological criteria dichotomized into Yes or No for severe
immunosuppression.

Table 3: Causes of deaths among the HIV-infected children within
12 months of highly active antiretroviral therapy.

Causes of death                        Number (%)

Within the first 6 months
Tuberculosis *                          21 (70)
Unknown #                               4 (13.3)
Sepsis/undernutrition                    3 (10)
Severe pneumonia                        2 (6.7)
Total                                   30 (100)
At the later 6 months of follow-up
Severe pneumonia                         4 (40)
Unknown #                                3 (30)
Tuberculosis ([section])                 3 (30)
Total                                   10 (100)

* The 21 children had prevalent tuberculosis with deaths
resulting from 11 of those with pulmonary tuberculosis, 7 with
tuberculosis meningitis/miliary tuberculosis, 2 with
gastrointestinal tuberculosis, and 1 with tuberculosis adenitis;
s
tuberculosis and 1 death from pulmonary tuberculosis; #caregivers
could only give history of febrile illness.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Anigilaje, Emmanuel Ademola; Aderibigbe, Sunday Adedeji
Publication:Advances in Medicine
Article Type:Report
Geographic Code:6NIGR
Date:Jan 1, 2018
Words:9526
Previous Article:The Prevalence of Abdominal Obesity and Its Correlates among the Adults in Dodoma Region, Tanzania: A Community-Based Cross-Sectional Study.
Next Article:Corrigendum to "Topical Colchicine Gel versus Diclofenac Sodium Gel for the Treatment of Actinic Keratoses: A Randomized, Double-Blind Study".
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters